Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection

Objectives: The simultaneous presence of cardiac and renal diseases is a pathological condition that leads to increased morbidity and mortality. Several lines of evidence have suggested that lipid dysmetabolism and mitochondrial dysfunction are pathways involved in the pathological processes affecting the heart and kidney. In the salt-loaded spontaneously hypertensive stroke-prone rat (SHRSP), a model of cardiac hypertrophy and nephropathy that shows mitochondrial alterations in the myocardium, we evaluated the cardiorenal effects of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR&agr;) agonist that acts by modulating mitochondrial and peroxisomal fatty acid oxidation. Methods: Male SHRSPs aged 6–7 weeks were divided in three groups: standard diet (n = 6), Japanese diet with vehicle (n = 6), and Japanese diet with fenofibrate 150 mg/kg/day (n = 6) for 5 weeks. Cardiac and renal functions were assessed in vivo by MRI, ultrasonography, and biochemical assays. Mitochondria were investigated by transmission electron microscopy, succinate dehydrogenase (SDH) activity, and gene expression analysis. Results: Fenofibrate attenuated cardiac hypertrophy, as evidenced by histological and MRI analyses, and protected the kidneys, preventing morphological alterations, changes in arterial blood flow velocity, and increases in 24-h proteinuria. Cardiorenal inflammation, oxidative stress, and cellular senescence were also inhibited by fenofibrate. In salt-loaded SHRSPs, we observed severe morphological mitochondrial alterations, reduced SDH activity, and down-regulation of genes regulating mitochondrial fatty-acid oxidation (i.e. PPAR&agr;, SIRT3, and Acadm). These changes were counteracted by fenofibrate. In vitro, a direct protective effect of fenofibrate on mitochondrial membrane potential was observed in albumin-stimulated NRK-52E renal tubular epithelial cells. Conclusion: The results suggest that the cardiorenal protective effects of fenofibrate in young male salt-loaded SHRSPs are explained by its capacity to preserve mitochondrial function.

[1]  P. Duann,et al.  Heme Oxygenase-1 in Kidney Health and Disease , 2019, Handbook of Mitochondrial Dysfunction.

[2]  J. Lim,et al.  PPARα agonist, fenofibrate, ameliorates age-related renal injury , 2016, Experimental Gerontology.

[3]  K. Doi,et al.  Mitochondrial Dysfunction in Cardiorenal Syndrome. , 2016, Antioxidants & redox signaling.

[4]  A. Benigni,et al.  Clinical Practice : Mini-Review , 2016 .

[5]  T. Ikizler,et al.  Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease , 2016, Physiological reports.

[6]  A. Fornoni,et al.  Systemic and renal lipids in kidney disease development and progression. , 2016, American journal of physiology. Renal physiology.

[7]  Robert W. Taylor,et al.  Impaired mitochondrial biogenesis is a common feature to myocardial hypertrophy and end-stage ischemic heart failure , 2016, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[8]  J. Schisler,et al.  Fenofibrate unexpectedly induces cardiac hypertrophy in mice lacking MuRF1. , 2016, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[9]  Wei Zhang,et al.  Activation of PPAR alpha by fenofibrate inhibits apoptosis in vascular adventitial fibroblasts partly through SIRT1-mediated deacetylation of FoxO1. , 2015, Experimental cell research.

[10]  M. Volpe,et al.  Protective effects of Brassica oleracea sprouts extract toward renal damage in high-salt-fed SHRSP: role of AMPK/PPAR&agr;/UCP2 axis , 2015, Journal of hypertension.

[11]  F. Nicoletti,et al.  Differential modulation of AMPK/PPARα/UCP2 axis in relation to hypertension and aging in the brain, kidneys and heart of two closely related spontaneously hypertensive rat strains , 2015, Oncotarget.

[12]  Saifudeen Ismael,et al.  Ligand specific variation in cardiac response to stimulation of peroxisome proliferator-activated receptor-alpha in spontaneously hypertensive rat , 2015, Molecular and Cellular Biochemistry.

[13]  Zhanjun Jia,et al.  Mitochondrial dysfunction confers albumin-induced NLRP3 inflammasome activation and renal tubular injury. , 2015, American journal of physiology. Renal physiology.

[14]  Dean P. Jones,et al.  Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3 , 2015, Nature Communications.

[15]  G. Remuzzi,et al.  Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. , 2015, Journal of Clinical Investigation.

[16]  M. Volpe,et al.  Pathogenesis of Target Organ Damage in Hypertension: Role of Mitochondrial Oxidative Stress , 2014, International journal of molecular sciences.

[17]  K. Ma,et al.  Activation of the Nlrp3 inflammasome by mitochondrial reactive oxygen species: a novel mechanism of albumin-induced tubulointerstitial inflammation. , 2014, The international journal of biochemistry & cell biology.

[18]  Jie Liu,et al.  Icariin Is A PPARα Activator Inducing Lipid Metabolic Gene Expression in Mice , 2014, Molecules.

[19]  D. Leibowitz Left Ventricular Hypertrophy and Chronic Renal Insufficiency in the Elderly , 2014, Cardiorenal Medicine.

[20]  Hao Li,et al.  Evidence for association of mitochondrial metabolism alteration with lipid accumulation in aging rats , 2014, Experimental Gerontology.

[21]  Songming Huang,et al.  Mitochondrial dysfunction in the pathophysiology of renal diseases. , 2014, American journal of physiology. Renal physiology.

[22]  A. Lupo,et al.  Downregulation of Nuclear-Encoded Genes of Oxidative Metabolism in Dialyzed Chronic Kidney Disease Patients , 2013, PloS one.

[23]  B. V. Van Tassell,et al.  Targeting interleukin-1 in heart disease. , 2013, Circulation.

[24]  R. Nagai,et al.  Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension. , 2013, International journal of cardiology.

[25]  Eric Verdin,et al.  Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor , 2013, Science.

[26]  A. Keech,et al.  Effects of fibrates in kidney disease: a systematic review and meta-analysis. , 2012, Journal of the American College of Cardiology.

[27]  P. McCullough,et al.  Fibrates and cardiorenal outcomes. , 2012, Journal of the American College of Cardiology.

[28]  P. Schulze,et al.  Lipid metabolism and toxicity in the heart. , 2012, Cell metabolism.

[29]  Hiroki Matsui,et al.  Stearoyl-CoA Desaturase-1 (SCD1) Augments Saturated Fatty Acid-Induced Lipid Accumulation and Inhibits Apoptosis in Cardiac Myocytes , 2012, PloS one.

[30]  Jun Ren,et al.  Mitochondria and Oxidative Stress in the Cardiorenal Metabolic Syndrome , 2012, Cardiorenal Medicine.

[31]  G. Remuzzi,et al.  Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. , 2011, American journal of physiology. Renal physiology.

[32]  D. Kelly,et al.  The PGC-1 cascade as a therapeutic target for heart failure. , 2011, Journal of molecular and cellular cardiology.

[33]  Sreeja Purushothaman,et al.  Reactivation of Peroxisome Proliferator-activated Receptor Alpha in Spontaneously Hypertensive Rat: Age-associated Paradoxical Effect on the Heart , 2011, Journal of cardiovascular pharmacology.

[34]  T. Noda,et al.  Inflammasome Activation of Cardiac Fibroblasts Is Essential for Myocardial Ischemia/Reperfusion Injury , 2011, Circulation.

[35]  J. Yatabe,et al.  Aldosterone/Mineralocorticoid receptor stimulation induces cellular senescence in the kidney. , 2011, Endocrinology.

[36]  J. Tschopp,et al.  A role for mitochondria in NLRP3 inflammasome activation , 2011, Nature.

[37]  E. Tremoli,et al.  Peroxisome Proliferator-Activated Receptor α Agonism Prevents Renal Damage and the Oxidative Stress and Inflammatory Processes Affecting the Brains of Stroke-Prone Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.

[38]  Weijie Yi,et al.  Mitochondrial HMG-CoA synthase partially contributes to antioxidant protection in the kidney of stroke-prone spontaneously hypertensive rats. , 2010, Nutrition.

[39]  Lakshmi Pulakat,et al.  Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease , 2010, Journal of Molecular Medicine.

[40]  W. Branham,et al.  Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury. , 2009, Kidney international.

[41]  G. Remuzzi,et al.  Disruption of the Ang II type 1 receptor promotes longevity in mice. , 2009, The Journal of clinical investigation.

[42]  S. Sihag,et al.  PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. , 2009, Journal of molecular and cellular cardiology.

[43]  Enrico G. Caiani,et al.  Analysis of regional left ventricular function in the post-infarct mouse by magnetic resonance imaging with retrospective gating , 2008, 2008 Computers in Cardiology.

[44]  C. Zhang,et al.  Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension , 2008, Journal of cellular and molecular medicine.

[45]  D. Allen,et al.  N‐Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice , 2008, The Journal of physiology.

[46]  G. Watts,et al.  Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. , 2008, Atherosclerosis.

[47]  G. Remuzzi,et al.  Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. , 2007, The American journal of pathology.

[48]  P. Kemmeren,et al.  Transcriptome-based identification of pro- and antioxidative gene expression in kidney cortex of nitric oxide-depleted rats. , 2007, Physiological Genomics.

[49]  S. Bakker,et al.  Albumin-bound fatty acids induce mitochondrial oxidant stress and impair antioxidant responses in proximal tubular cells. , 2006, Kidney international.

[50]  A. Garg,et al.  Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.

[51]  S. Soyal,et al.  PGC-1α: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes , 2006, Diabetologia.

[52]  M. Breyer,et al.  Liver X receptor agonist TO-901317 upregulates SCD1 expression in renal proximal straight tubule. , 2006, American journal of physiology. Renal physiology.

[53]  B. Krumme,et al.  Renal Doppler Sonography – Update in Clinical Nephrology , 2006, Nephron Clinical Practice.

[54]  J. McManaman,et al.  Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. , 2005, Diabetes.

[55]  C. Franceschi,et al.  A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. , 2005, Genomics.

[56]  E. Schiffrin,et al.  Eplerenone Prevents Salt-Induced Vascular Remodeling and Cardiac Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats , 2004, Hypertension.

[57]  Laura C. Greaves,et al.  Mitochondrial DNA mutations in human colonic crypt stem cells. , 2003, The Journal of clinical investigation.

[58]  E. Lonn,et al.  Cardiovascular risk in patients with mild renal insufficiency. , 2003, Kidney international. Supplement.

[59]  D. Grobbee,et al.  Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. , 2003, European heart journal.

[60]  M. Miyazaki,et al.  Role of stearoyl-coenzyme A desaturase in lipid metabolism. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[61]  J. Megyesi,et al.  Positive effect of the induction of p21WAF1/CIP1 on the course of ischemic acute renal failure. , 2001, Kidney international.

[62]  H. Taegtmeyer,et al.  Reactivation of Peroxisome Proliferator-activated Receptor α Is Associated with Contractile Dysfunction in Hypertrophied Rat Heart* , 2001, The Journal of Biological Chemistry.

[63]  E. Tremoli,et al.  Acute-Phase Proteins Before Cerebral Ischemia in Stroke-Prone Rats: Identification by Proteomics , 2001, Stroke.

[64]  D. Kelly,et al.  Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. , 2000, The Journal of clinical investigation.

[65]  T W Wilson,et al.  Fenofibrate lowers blood pressure in two genetic models of hypertension. , 2000, Canadian journal of physiology and pharmacology.

[66]  J. Mehlsen,et al.  The pulsatility index and the resistive index in renal arteries. Associations with long-term progression in chronic renal failure. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[67]  H. Ito,et al.  Alterations in mitochondrial DNA and enzyme activities in hypertrophied myocardium of stroke-prone SHRS. , 1996, Clinical and experimental hypertension.

[68]  G. Kroemer,et al.  Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death , 1995, The Journal of experimental medicine.

[69]  A. Sbarbati,et al.  Protective action of lacidipine in cardiac hypertrophy of the spontaneously hypertensive stroke-prone rat: an ultrastructural study. , 1994, Journal of submicroscopic cytology and pathology.

[70]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[71]  Aditya P. Dandekar,et al.  Cross talk between ER stress, oxidative stress, and inflammation in health and disease. , 2015, Methods in molecular biology.

[72]  J. Tomassini,et al.  Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. , 2013, Journal of atherosclerosis and thrombosis.

[73]  Chi-hung Cheng,et al.  Interleukin 1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism in patients with end-stage renal failure. , 2005, Renal failure.

[74]  I Jurisica,et al.  Alterations in mitochondrial membrane potential during preimplantation stages of mouse and human embryo development. , 2004, Molecular human reproduction.

[75]  B. Cha,et al.  Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. , 2003, Diabetes/metabolism research and reviews.

[76]  R. Atkins,et al.  Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. , 1999, Kidney international.

[77]  J. Joles,et al.  Hyperlipidemia is secondary to proteinuria and is completely normalized by angiotensin-converting enzyme inhibition in hypertensive fawn-hooded rats. , 1997, Nephron.